Ramucirumab (CAS 947687-13-0) – Anti-VEGFR2 Monoclonal Antibody Anticancer API

Ramucirumab (CAS 947687-13-0) is a high-purity pharmaceutical API classified as a VEGFR2 inhibitor, featuring a recombinant human IgG1 monoclonal antibody structure engineered to target vascular endothelial growth factor receptor 2 (VEGFR2). It binds specifically to VEGFR2, blocking its interaction with VEGF ligands to inhibit tumor angiogenesis—cutting off the blood supply that fuels tumor growth and metastasis. This premium API exhibits high specificity and stable bioactivity, ensuring consistent performance in intravenous injectable formulations.

It caters to the core needs of oncology drug manufacturers, biotech research institutions, and clinical trial suppliers. Widely applied in developing treatments for advanced gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma, it aligns with the demand for anti-angiogenic anticancer therapies. Produced under strict GMP-compliant biomanufacturing processes, each batch undergoes rigorous purity and potency testing to meet global biopharmaceutical standards. For businesses prioritizing targeted, anti-angiogenic cancer solutions, this Ramucirumab API serves as a critical raw material for advancing oncology therapy research and clinical applications.